Cargando…
Sotrastaurin, a PKC inhibitor, attenuates RANKL‐induced bone resorption and attenuates osteochondral pathologies associated with the development of OA
Osteoarthritis (OA) is a common degenerative disease that affects the musculoskeletal structure of the whole joint, which is characterized by progressive destruction of both articular cartilage and subchondral bone. Treatment of the bone pathologies, particularly osteoclast‐mediated subchondral bone...
Autores principales: | Pang, Cong, Wen, Liangbao, Qin, Haikuo, Zhu, Bikang, Lu, Xuanyuan, Luo, Shixing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412701/ https://www.ncbi.nlm.nih.gov/pubmed/32652826 http://dx.doi.org/10.1111/jcmm.15404 |
Ejemplares similares
-
Egg White Ovotransferrin Attenuates RANKL-Induced Osteoclastogenesis and Bone Resorption
por: Shang, Nan, et al.
Publicado: (2019) -
Nardosinone Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Lipopolysaccharide-Induced Alveolar Bone Resorption
por: Niu, Chenguang, et al.
Publicado: (2017) -
Water extract of Uncaria sinensis suppresses RANKL-induced bone loss by attenuating osteoclast differentiation and bone resorption
por: Ha, Hyunil, et al.
Publicado: (2017) -
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma
por: Bauer, Sebastian, et al.
Publicado: (2023) -
A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
por: Shoushtari, Alexander N., et al.
Publicado: (2021)